Back to Search
AMANDA CALVERT, PHARMD
PHARMD
Pharmacist
NPI: 1992283931Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
27915(NC)
Research & Publications (20)
Seismic reflection imaging of two megathrust shear zones in the northern Cascadia subduction zone.
PMID 15014496·Nature·2004
8-other
Investigations into the lack of consensus in the reporting of HLA antibody specificities in the UK.
PMID 19251955·J Clin Pathol·2009
4-observational
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
PMID 19091546·Eur J Cancer·2009
6-review
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
PMID 17890079·Eur J Cancer·2008
8-other
Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer.
PMID 18495208·Hum Pathol·2008
8-other
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
PMID 18559580·Clin Cancer Res·2008
8-other
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
PMID 17845846·Eur J Cancer·2008
8-other
Six sigma methodology can be used to improve adherence for antibiotic prophylaxis in patients undergoing noncardiac surgery.
PMID 17179259·Anesth Analg·2007
8-other
Glycosylation of the dengue 2 virus E protein at N67 is critical for virus growth in vitro but not for growth in intrathoracically inoculated Aedes aegypti mosquitoes.
PMID 17543367·Virology·2007
7-preclinical
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
PMID 16707462·Cancer Res·2006
7-preclinical
Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge.
PMID 16432020·J Gen Virol·2006
7-preclinical
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
PMID 15867241·Clin Cancer Res·2005
3-trial
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
PMID 16278406·Clin Cancer Res·2005
3-trial
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
PMID 15699482·J Clin Oncol·2005
3-trial
Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.
PMID 15713419·Bioorg Med Chem Lett·2005
8-other
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
PMID 15756276·Br J Cancer·2005
3-trial
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
PMID 15385119·Gynecol Oncol·2004
3-trial
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.
PMID 15481984·J Med Chem·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10250 S MAIN ST
ARCHDALE, NC 27263 - Phone
- (336) 804-6051
Quick Facts
- NPI
- 1992283931
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile